Cubit Diagnostics Secures $2.6 Million in RADx® Tech Funding to Advance High-Sensitivity, Low-Cost Multi-modal Diagnostic Platform
[Carlsbad, 4th February 2025]
Cubit Diagnostics is proud to announce it was awarded $2.6 million through the National Institutes of Health (NIH) RADx® (Rapid Acceleration of Diagnostics) Tech program on December 2, 2024, marking a significant milestone in its mission to revolutionize point-of-care diagnostics with lab-level sensitivity and unmatched affordability. This funding will be used to complete the development of the Cubit Covid/Flu A/Flu B test for clinical trials.
The funding will enable CubitDx to accelerate the development and scaling of its innovative diagnostic platform, which achieves greater sensitivity from all sample types including blood than current rapid tests while maintaining a low-cost, user-friendly form factor.
“This award is transformative for Cubit Diagnostics,” said Kunal Sur, CEO of CubitDx. “It allows us to complete platform development, get our first assay ready for a clinical study, reduce instrument and consumable cost, and work toward delivering lab-quality results within 15 minutes at thepoint of care. Our vision is to bring high-performance diagnostics closer to patients, improving outcomes and accessibility worldwide.”
1. Addressing Critical Gaps in Diagnostics
CubitDx’s platform tackles longstanding challenges in diagnostics by combining cutting-edge target extraction technology with an intuitive, low-cost design. The result is central lab-level performance without compromising affordability, enabling distributed care and supporting the growing trend of digital health.
Evaluations at Emory University demonstrated that the CubitDx platform COVID-19 assay delivers higher sensitivity than standard rapid tests and matches the sensitivity of large, high-throughput clinical lab systems.
2. Partnerships and Collaboration
CubitDx’s success is driven by key collaborations, including technical support from Arete Biosciences, support from the RADx Tech program These partnerships have been pivotal in refining the platform and validating its performance.
3. A Platform for the Future of Diagnostics
While initially focused on Covid/Flu A/Flu B, the CubitDx platform is designed to address a broad spectrum of critical health conditions in the future, including:
- Sepsis
- Sexually transmitted diseases (STDs)
- HIV and HPV
With its ability to deliver affordable, high-sensitivity diagnostics in both resource-rich and cost-sensitive markets, CubitDx is positioned to transform healthcare access globally, from hospitals in the U.S.to underserved communities across Asia and Africa.
4. Looking Ahead
“This funding reaffirms our mission to push the boundaries of diagnostics,” added Kunal Sur. “We’re not just building another diagnostic tool—we’re laying the foundation for the next generation of diagnostics that will save lives, lower costs, and prevent future pandemics.”
---
For more information about CubitDx and its groundbreaking diagnostic technology, visit www.cubitdx.com
---
5. About Cubit Diagnostics
Cubit Diagnostics is redefining point-of-care testing with its innovative platform that combines lab-level sensitivity, rapid turnaround times, and unmatched affordability. With applications ranging from infectious disease to global healthcare solutions, CubitDx is committed to enabling accessible diagnostics that drive better health outcomes for all.
This project has been funded in part with Federal funds from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), National Institutes of Health, Department of Health and Human Services, under Contract No. 75N92023D00001.